Reporter Molecule for Study of Alzheimer's Disease

Back to all technologies
Download as PDF
2019-CHOP-68541
Researchers at Purdue University have developed pH-dependent fluorogenic amyloid-beta reporters for the study of Alzheimer's disease (AD). Microglial phagocytosis of amyloid-beta peptides is a critical step in the regulation of brain homeostasis during the initiation and progression of AD. Unlike common methods to study this phenomenon, this technology is specific for amyloid-beta and functions in live cells. The reporter, an isoform of human amyloid-beta tagged with a pH-dependent fluorogenic moiety, fluoresces only upon phagocytosis in the acidic intracellular phagosomes. It clearly differentiates between phagocytic and non-phagocytic cells within live human and nonhuman microglial cells. This technology promises to aid in the discovery of new therapeutics for AD.

Advantages:
-Facilitates live cell tracking of microglial phagocytosis
-Differentiates between phagocytic and non-phagocytic microglial cells

Potential Applications:
-Development of Alzheimer's Therapeutics
Mar 27, 2020
PCT-Patent
WO
(None)
(None)

Mar 29, 2019
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org